Organization and Business	12 Months Ended
Dec. 31, 2015
Organization and Business [Abstract]
Organization and Business	1. Organization and Business Progenics Pharmaceuticals, Inc. ("Progenics," "we" or "us") develops innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer (AZEDRA^®, 1095 and PSMA ADC), and imaging agents (1404 and PyL) intended to enable clinicians and patients to accurately visualize and manage their disease. In addition, as part of its acquisition of EXINI Diagnostics AB ("EXINI") in late 2015, Progenics acquired the EXINI Bone BSI bone scan index product, which is approved for use in Europe, Japan and the U.S. (though not yet available in the U.S.). EXINI BoneBSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool "reads" bone scans and produces a standard, automated Bone Scan Index quantification. We licensed our first commercial drug, RELISTOR^® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid induced constipation ("OIC"), to Salix Pharmaceuticals, Inc.(a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant")). In June 2015, a New Drug Application for oral RELISTOR (methylnaltrexone bromide) Tablets was submitted by Valeant to the U.S. Food and Drug Administration ("FDA") for the treatment of OIC in adult patients with chronic non-cancer pain. In September 2015, the FDA assigned this New Drug Application for oral RELISTOR a Prescription Drug User Fee Act action date of April 19, 2016. In September 2014 RELISTOR received an expanded approval from the U.S. Food and Drug Administration for the treatment of OIC in patients taking opioids for chronic non-cancer pain. We have partnered other internally-developed or acquired compounds and technologies with third parties. We continue to consider opportunities for strategic collaborations, out-licenses and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and may in the future also in-license or acquire additional oncology compounds and/or programs. Our current principal sources of revenue from operations are royalty, development and commercial milestones and sublicense revenue-sharing payments from Valeant's RELISTOR operations. Royalty and milestone payments from RELISTOR depend on success in development and commercialization, which is dependent on many factors, such as Valeant's efforts, decisions by the FDA and other regulatory bodies, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of RELISTOR. In 2014, we recognized a $40 million milestone payment from Valeant related to market approval for subcutaneous RELISTOR. We have historically funded our operations to a significant extent from capital-raising. During 2014, we raised $37.5 million in an underwritten public offering of 8.75 million shares of common stock at a public offering price of $4.60 per share, and entered into an agreement with an investment bank under which we may sell from time to time up to $50 million of our stock. During 2013, we completed an underwritten public offering of 9.8 million shares of common stock at a public offering price of $4.40 per share, resulting in net proceeds of approximately $40.1 million. Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. Certain of our intellectual property rights are held by wholly owned subsidiaries. All of our U.S. operations are conducted at our facilities in Tarrytown, New York, and our international operations are conducted at our facilities in Lund, Sweden. We operate under a single research and development segment. Funding and Financial Matters. At December 31, 2015, we held $74.1 million in cash and cash equivalents, a decrease of $45.2 million from $119.3 million at December 31, 2014. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We expect to require additional funding in the future, the availability of which is never guaranteed and may be uncertain. We expect that we may continue to incur operating losses for the foreseeable future.

1. Organization and Business

Progenics Pharmaceuticals, Inc. ("Progenics," "we" or "us") develops innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer (AZEDRA^®, 1095 and PSMA ADC), and imaging agents (1404 and PyL) intended to enable clinicians and patients to accurately visualize and manage their disease. In addition, as part of its acquisition of EXINI Diagnostics AB ("EXINI") in late 2015, Progenics acquired the EXINI Bone BSI bone scan index product, which is approved for use in Europe, Japan and the U.S. (though not yet available in the U.S.). EXINI BoneBSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool "reads" bone scans and produces a standard, automated Bone Scan Index quantification.

We licensed our first commercial drug, RELISTOR^® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid induced constipation ("OIC"), to Salix Pharmaceuticals, Inc.(a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant")). In June 2015, a New Drug Application for oral RELISTOR (methylnaltrexone bromide) Tablets was submitted by Valeant to the U.S. Food and Drug Administration ("FDA") for the treatment of OIC in adult patients with chronic non-cancer pain. In September 2015, the FDA assigned this New Drug Application for oral RELISTOR a Prescription Drug User Fee Act action date of April 19, 2016. In September 2014 RELISTOR received an expanded approval from the U.S. Food and Drug Administration for the treatment of OIC in patients taking opioids for chronic non-cancer pain. We have partnered other internally-developed or acquired compounds and technologies with third parties. We continue to consider opportunities for strategic collaborations, out-licenses and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and may in the future also in-license or acquire additional oncology compounds and/or programs.

Our current principal sources of revenue from operations are royalty, development and commercial milestones and sublicense revenue-sharing payments from Valeant's RELISTOR operations. Royalty and milestone payments from RELISTOR depend on success in development and commercialization, which is dependent on many factors, such as Valeant's efforts, decisions by the FDA and other regulatory bodies, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of RELISTOR. In 2014, we recognized a $40 million milestone payment from Valeant related to market approval for subcutaneous RELISTOR.

We have historically funded our operations to a significant extent from capital-raising. During 2014, we raised $37.5 million in an underwritten public offering of 8.75 million shares of common stock at a public offering price of $4.60 per share, and entered into an agreement with an investment bank under which we may sell from time to time up to $50 million of our stock. During 2013, we completed an underwritten public offering of 9.8 million shares of common stock at a public offering price of $4.40 per share, resulting in net proceeds of approximately $40.1 million.

Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. Certain of our intellectual property rights are held by wholly owned subsidiaries. All of our U.S. operations are conducted at our facilities in Tarrytown, New York, and our international operations are conducted at our facilities in Lund, Sweden. We operate under a single research and development segment.

Funding and Financial Matters. At December 31, 2015, we held $74.1 million in cash and cash equivalents, a decrease of $45.2 million from $119.3 million at December 31, 2014. We expect that this amount will be sufficient to fund operations as currently anticipated beyond one year. We expect to require additional funding in the future, the availability of which is never guaranteed and may be uncertain. We expect that we may continue to incur operating losses for the foreseeable future.